FLT3 Inhibitors in AML.

Slides:

Advertisements

Similar presentations

Results of a Phase 2 Randomised, Open- Label, Study of Lower Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory.

Advertisements

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

1 Stone RM et al. Proc ASH 2015;Abstract 6.

Maury S et al. Proc ASH 2015;Abstract 1.

CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory FLT3-IDT AML CCO Independent Conference.

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Platzbecker U et al. Proc ASH 2014;Abstract 12.

RATIFY: Midostaurin Added to Standard Chemotherapy Prolongs OS in Patients With Newly Diagnosed FLT3-Mutated AML New Findings in Hematology: Independent.

Finding the Right Fit: Personalizing Treatment in Metastatic Castration-Resistant Prostate Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

New Horizons for SMA.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Updates and Insights on the Medical Science of Prostate Cancer

Improving Survival in Glioblastoma Multiforme

Targeting FLT3 Mutations in Acute Myeloid Leukemia

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Applying New Data in Practice:

Immune Reconstitution in MS:

Expert Perspectives on Best Practices for Diagnosis and Management of Spinal Muscular Atrophy.

New Standards of Care in ALK-Translocated Advanced NSCLC

Mutations and AML: Sampling, Assays, and Interpreting Results

Prolonging Progression-Free Survival in Follicular Lymphoma

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

PARP Inhibitors and Cancer: What Do You Need to Know?

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Advances in Myeloid Malignancies

Management Challenges in CLL

Individualizing Care in Ovarian Cancer

Case Studies in Unresectable Hepatocellular Carcinoma

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

EHA Stockholm 2018 Deepak Mannari.

How to Select Therapy In Newly Diagnosed CLL

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Myeloid Updates From the Summer Congresses

Updates in the Management of Acute Promyelocytic Leukemia

Getting to Grips With the Science of CGRP and Migraine

PARP Inhibitors.

Locally Advanced Lung Cancer

Chronic Myeloid Leukemia Challenge

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Best Practices in SMA.

Molecular Testing in Ovarian Cancer: Is the Time Now?

Managing Your Patient’s Maintenance Therapy for Multiple Myeloma

New ELN Recommendations

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Practical Guidance on the Management of Pan-Negative NSCLC

Short title / Key scientific finding

Patient and Clinician Perspectives on Preventive Therapy for Migraine

What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Role of Measurable Residual Disease in AML

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

New Paradigms in M0 CRPC.

IDH Inhibitors in AML.

Checkpoint Inhibitors in First-Line Advanced NSCLC

CDK4/6 Inhibitors.

Going Beyond EXTREME in Head and Neck Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Program. Applying the Data and Practical Recommendations for Tailoring Treatment Selections for AML.

by Jan J. Cornelissen, and Didier Blaise

The Power of As-Treated Analyses

Presentation transcript:

FLT3 Inhibitors in AML

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Mutational Complexity of AML

FLT3 Mutations in AML

FLT3 Inhibitors in Clinical Development

7+3/Midostaurin vs 7+3/Placebo Phase 3 CALGB 10603 (RATIFY)[a]

OS CALGB 10603 (RATIFY), Phase 3

OS After AlloHSCT in CR1 CALGB 10603 (RATIFY), Phase 3

DFS During Maintenance CALGB 10603 (RATIFY), Phase 3

DFS After Maintenance CALGB 10603 (RATIFY), Phase 3

Gilteritinib in FLT3-Mutated R/R AML CHRYSALIS, Phase 1/2

ADMIRAL TRIAL – Gilteritinib in R/R AML

Quizartinib in FLT3-ITD+ R/R AML Randomized Phase 2 Study

QuANTUM-R Study Design

QuANTUM-R Primary Endpoint Overall Survival by Kaplan-Meier Method

QuANTUM-R Best Response

Comparison of Primary and Prespecified Sensitivity Analyses of OS in QuANTUM-R

Crenolanib in FLT3-Mutated R/R AML Phase 2 Results

Dose-Ranging Study of Gilteritinib in ND AML Updated Results at ASH 2018

Quizartinib With Standard Chemotherapy in ND AML Phase 1b Study

Crenolanib With Standard AML Therapy Phase Ib Study

Sorafenib Plus Azacytidine FLT3-ITD+ R/R AML, Phase 2 Study

Sorafenib Plus Azacytidine Newly Diagnosed FLT3-ITD+ AML

Quizartinib Plus Azacytidine or LDAC Phase 1/2 Trial

FLT3 Inhibitors as Maintenance Post-AlloSCT

Applying Recent Data to the Clinic

Practical Issues in FLT3 Mutation Testing Expert Perspectives

When Can You Give FLT3 Inhibitors?

FLT3 Inhibitors as a Bridge to Transplant?

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)